Kymera Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Kymera Therapeutics (KYMR).

Price Target Range — 12 Quarters

Analyst Consensus — 24 Analysts

21Buy

3Hold

Consensus RatingBuy# Analysts24Avg. Consensus PT$113Upside to Avg. PT+5.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 22, 2026	Stifel	Alex Thompson	PT Raise	Buy	$132→$152
Sep 14, 2026	B of A Securities	Tazeen Ahmad	PT Raise	Buy	$123→$144
Sep 10, 2026	Wolfe Research	Andy Chen	Upgrade	Peer Perform→Outperform	—
Aug 31, 2026	Guggenheim	Brad Canino	PT Raise	Buy	$135→$170
Aug 27, 2026	Wells Fargo	Derek Archila	PT Raise	Overweight	$116→$151
Aug 6, 2026	Barclays	Eliana Merle	PT Raise	Overweight	$133→$139
Jul 30, 2026	Deutsche Bank	David Hoang	Initiate	Hold	$120
Jul 28, 2026	Guggenheim	Brad Canino	PT Raise	Buy	$125→$135
Jul 16, 2026	Mizuho	Joseph Catanzaro	PT Raise	Outperform	$120→$140
Jul 13, 2026	RBC Capital	Brian Abrahams	Downgrade	Outperform→Sector Perform	$106→$115
Jun 30, 2026	B of A Securities	Tazeen Ahmad	PT Raise	Buy	$110→$125
Jun 29, 2026	Truist Securities	Srikripa Devarakonda	PT Raise	Buy	$116→$136
Jun 29, 2026	B. Riley Securities	Kalpit Patel	PT Raise	Buy	$117→$155
Jun 26, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$106→$129
Jun 25, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$134
May 6, 2026	Canaccord Genuity	Edward Nash	Initiate	Buy	$106
Mar 16, 2026	Jefferies	Faisal Khurshid	Assumes	Buy	$122→$110
Mar 3, 2026	UBS	David Dai	PT Raise	Buy	$90→$128
Mar 2, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$110→$120
Mar 2, 2026	Stephens & Co.	Sudan Loganathan	PT Raise	Overweight	$95→$100

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Stifel Maintains Buy on Kymera Therapeutics, Raises Price Target to $152

Stifel analyst Alex Thompson maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $132 to $152.

Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $144

B of A Securities analyst Tazeen Ahmad maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $123 to $144.

Benzinga Newsdesk

PRO
Wolfe Research Upgrades Kymera Therapeutics to Outperform

Wolfe Research analyst Andy Chen upgrades Kymera Therapeutics (NASDAQ:KYMR) from Peer Perform to Outperform.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $170

Guggenheim analyst Brad Canino maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $135 to $170.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Kymera Therapeutics, Raises Price Target to $151

Wells Fargo analyst Derek Archila maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $116 to $151.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $139

Barclays analyst Eliana Merle maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $133 to $139.

Benzinga Newsdesk

Kymera Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Kymera Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Stifel Maintains Buy on Kymera Therapeutics, Raises Price Target to $152

PRO
B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $144

PRO
Wolfe Research Upgrades Kymera Therapeutics to Outperform

PRO
Guggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $170

PRO
Wells Fargo Maintains Overweight on Kymera Therapeutics, Raises Price Target to $151

PRO
Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $139

People Also Watch

People Also Watch

Kymera Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Kymera Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROStifel Maintains Buy on Kymera Therapeutics, Raises Price Target to $152

PROB of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $144

PROWolfe Research Upgrades Kymera Therapeutics to Outperform

PROGuggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $170

PROWells Fargo Maintains Overweight on Kymera Therapeutics, Raises Price Target to $151

PROBarclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $139

People Also Watch

People Also Watch

PRO
Stifel Maintains Buy on Kymera Therapeutics, Raises Price Target to $152

PRO
B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $144

PRO
Wolfe Research Upgrades Kymera Therapeutics to Outperform

PRO
Guggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $170

PRO
Wells Fargo Maintains Overweight on Kymera Therapeutics, Raises Price Target to $151

PRO
Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $139